Dr Reddy's Lab slips on recall of Rivastigmine Tartrate Capsules from USA

Shares of pharma major Dr Reddy’s Lab have slipped over 3.5% at Rs 4,089 on the BSE after the company initiated a voluntary recall of Rivastigmine Tartrate Capsules of 1.5 mg strength from the USA market, following failed dissolution specifications. 

The company recalled a total of 60 bottles of 2952 units as directed by the US Food and Drug Administration (USFDA).

According to a notification issued by the agency, the batch was manufactured at Dr Reddy Lab, Bachupally unit and the recall was initiated under "Class II" classification.

Rivastigmine Tartrate Capsules are indicated for the treatment of mild to moderate dementia of the Alzheimer's type or Parkinson's disease.

The stock opened at Rs 4,199.95 and touched a low of Rs 4,056 on the BSE. A total of 6,467 shares changed hands on the BSE.